Principal Fellow

René Bruno


“After having worked with gRED Clinical Pharmacology as a consultant for several years, I wanted to join the company to have a greater impact on development programs. Institut Roche gave me this opportunity to work with Genentech (gRED Clinical Pharmacology) while being based in France.”

Your role at Institut Roche and brief presentation of your professional background:

I am a Pharmacometrician and Clinical Pharmacologist with close to 40 years of modeling and drug development experience in academic (3 years), consulting (13 years) and industry (23 years). I joined Institut Roche in 2016 as a Staff Scientist. My role is to support the development of the gRED oncology portfolio as Modeling and Simulation (M&S) expert within the Department of Clinical Pharmacology. I am the M&S Lead for Atezolizumab (Tecentriq).

My Focus at Institut Roche:

Development of tumor growth Inhibition (TGI) models and models linking TGI to overall survival (OS) to support oncology drug development, from early clinical trial decisions to personalized health care (PHC).

  1. WU B, STERNHEIM N, AGARWAL P, SUCHOMEL J, VADHAVKAR S, BRUNO R, BALLINGER M, BERNAARDS CA, CHAN P, RUPPEL J, JIN J, GIRISH S, JOSHI A, QUARMBY V. Evaluation of Atezolizumab Immunogenicity: Clinical Pharmacology (Part 1). Clinical and Translational Science. 15,130-140, 2022.
  2. PETERS S, GALLE PR, BERNAARDS CA, BALLINGER M, BRUNO R, QUARMBY V, RUPPEL J, VILIMOVSKIJ A, WU B, STERNHEIM N, RECK M. Evaluation of Atezolizumab Immunogenicity: Efficacy and Safety (Part 2). Clinical and Translational Science. 15, 141-157, 2022.
  3. KERIOUI M, BERTRAND J, BRUNO R, MERCIER F, GUEDJ J, DESMÉE S. Modelling the association between biomarkers and clinical outcome: an introduction to nonlinear joint models. British Journal of Clinical Pharmacology, 2022;1-12. doi:10.1111/bcp.15200. (Invited Review).
  4. CHAN P, LU J, BRUNO R, JIN J. Update to improve reproducibility and interpretability: A response to “Machine Learning for Tumor Growth Inhibition”. Clinical Pharmacology and Therapeutics: Pharmacometrics & Systems Pharmacology, 11, 262-263, 2022.
  5. KERIOUI M, DESMÉE S, MERCIER F, LIN A, WU B, SHEN X, LE TOURNEAU C, JIN YJ, BRUNO R, GUEDJ J. Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy. ESMO Open, 7:100346, 2022. doi: 10.1016/j.esmoop.2021.100346.
  6. LIU SN, MARCHAND M, LIN A, LIU X, MAIYA V, WU B, BRUNO R. Extension of the Flexible IV Atezolizumab Dosing Regimens into the Combination Setting Through Modeling and Simulation. Journal of Clinical Pharmacol, in revision with minor comments.
  7. YOSHIDA K, CHAN P, MARCHAND M, ZHANG R, WU B, BALLINGER M, STERNHEIM N, JIN YJ. BRUNO R. Tumor growth inhibition-overall survival (TGI-OS) model for subgroup analysis based on post-randomization factors: application for anti-drug antibody (ADA) subgroup analysis in IMpower150 study. AAPS Journal, accepted April 13, 2022.
  8. WU B, LIU SN, BALLINGER M, STERNHEIM N, PATEL H, MAZIERES J, BRUNO R. Letter to the Editor: Model-based simulation to support the extended dosing regimens of atezolizumab. European Journal of Clinical Pharmacology, 77, 1065-1066, 2021.
  9. CHANU P, MUSIB L, WANG X, CHEETI S, GIRISH S, BRUNO R, LU T, REDDY J, JIN JY, CARO I. Vismodegib efficacy in advanced basal cell carcinoma maintained with 8-week dose interruptions: A model-based evaluation. Journal of Investigative Dermatology, 141, 930-933, 2021.
  10. SHEMESH CS, CHAN P, LEGRAND F.A, SHAMES DS, DAS THAKUR M, SHI J, BAILEY L, VADHAVKAR S, HE X, ZHANG W, BRUNO R. Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumour mutational burden. Pharmacology Research & Perspectives, 8, e00685, 2020. DOI: 10.1002/prp2.685.
  11. CHAN P, ZHOU X, WANG N, LIU Q, BRUNO R, JIN JY. Application of Machine Learning for Tumor Growth Inhibition – Overall Survival Modeling Platform. Clinical Pharmacology Therapeutics: Pharmacometrics & Systems Pharmacology, 10, 59-66, 2021.
  12. SHEMESH C.S, CHAN P, SHAO H, XU D.Z, COMBS D, VADHAVKAR S, BRUNO R, WU B. Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. Liver Cancer, 10, 485-499, 2021.
  13. MARCHAND M, ZHANG R, CHAN P, QUARMBY V, BALLINGER M, STERNHEIM N, WU B, JIN JY, BRUNO R. Time-Dependent Population PK Models of Single Agent Atezolizumab in Patients with Cancer. Cancer Chemotherapy and Pharmacology, 88, 211-221, 2021.
  14. KAWAKATSU S, BRUNO R, KÅGEDAL M, LI C, GIRISH S, JOSHI A, WU B. Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology. British Journal of Clinical Pharmacology, 87, 2493-2501, 2021.
  15. CHAN P, MARCHAND M, YOSHIDA K, VADHAVKARA S, WANG N, LIN A, WU B, BALLINGER M, STERNHEIM N, JIN Y.J, BRUNO R. Prediction of overall survival in patients across solid tumors following atezolizumab treatments: a TGI-OS modeling framework. Clinical Pharmacology and Therapeutics: Pharmacometrics & Systems Pharmacology, 10, 1171-1182, 2021.
  16. KRISHNAN S, FRIBERG L, BRUNO R, BEYER Y, JIN J, KARLSSON M. Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel. Clinical Pharmacology and Therapeutics: Pharmacometrics & Systems Pharmacology, 10, 1255-1266, 2021.
  17. NETTERBERG I, BRUNO R, CHEN Y-C, WINTER H, LI C-C, JIN J, FRIBERG L. The tumor time-course predicts overall survival in non-small cell lung cancer patients treated with atezolizumab – dependency on follow-up time. Clinical Pharmacology and Therapeutics: Pharmacometrics & Systems Pharmacology. 9, 115-123, 2020.
  18. MERCIER F, KERIOUI M, DESMÉE S, GUEDJ J, KRIETER O, BRUNO R. Longitudinal analysis of organ-specific tumor lesion size in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment. Journal of Pharmacokinetics and Pharmacodynamics, 47, 613-625, 2020.
  19. KERIOUI M, MERCIER F, BERTRAND J, TARDIVON C, BRUNO R, GUEDJ J, DESMÉE S. Bayesian inference using Hamiltonian Monte-Carlo algorithm for nonlinear joint modelling in the context of cancer immunotherapy. Statistics in Medicine, 39, 4853-4868, 2020.
  20. BRUNO R, BOTTINO D, DE ALWIS DP, FOJO T, GUEDJ J, LIU C, SWANSON KR, ZHENG JJ, ZHENG Y, JIN JY. Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamics Models. Clinical Cancer Research, 26, 1787-1795, 2020 (Invited Review).
  21. HAMID O, BRUNO R, FASSO M, O’HEAR C, WU B. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab—Response. Clinical Cancer Research, 26, 2436, 2020.
  22. BRUNO R, JIN YJ, MAXFIELD K, MILLIGAN L, LIU C, WANG Y, MCKEE A.E, ZINEH I. Proceedings of a Workshop: US Food and Drug Administration‐International Society of Model‐Informed Drug Development in Oncology. Clinical Pharmacology and Therapeutics, 106, 81-83, 2019 (Invited Conference Report).
  23. TARDIVON C, DESMÉE S, KERIOUI M, BRUNO R, WU B, MENTRÉ F, MERCIER F, GUEDJ J. Association between tumor size kinetics and survival in urothelial carcinoma patients treated with atezolizumab: implication for patient’s follow-up. Clinical Pharmacology and Therapeutics, 106, 810-820, 2019.
  24. MORRISSEY KM, MARCHAND M, PATEL H, ZHANG R, WU B, CHAN P, MECKE A, GIRISH S, JIN YJ, WINTER HR, BRUNO R. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother and Pharmacology, 84:1257-1267, 2019.
  25. SHEMESH C.S, CHANU P, JAMSEN K, WADA R, ROSSATO G, DONALDSON F, GARG A. WINTER H, RUPPEL J, WANG X, BRUNO R, JIN J, GIRISH S. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Journal for ImmunoTherapy of Cancer, 7, 314, 2019.
  26. CLARET L., PENTAFRAGKA C. KAROVIC S., ZHAO B., SCHWARTZ L.H., MAITLAND ML, BRUNO R. – Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study. Cancer Chemotherapy Pharmacology, [Epub ahead of print], Apr 26, 2018 doi: 10.1007/s00280-018-3587-7.
  27. CLARET L., JIN J.Y., FERTÉ C., WINTER H., GIRISH S., STROH M., HE P., BALLINGER M., SANDLER A., JOSHI A., RITTMEYER A., GANDARA D., SORIA J.-C., BRUNO R. – A model of overall survival predicts treatment outcomes with atezolizumab vs chemotherapy in non-small cell lung cancer based on early tumor kinetics. Clinical Cancer Research, 24, 3292-3298, 2018.
  28. CHATELUT E, BRUNO R, RATAIN M. Intraindividual pharmacokinetic variability: focus on small molecule kinase inhibitors. Clinical Pharmacology and Therapeutics, 103, 956-958, 2018.
  29. HAN K., CHANU P., JONSSON F., WINTER H., BRUNO R., JIN J., STROH M. – Exposure–response and tumor growth inhibition analyses of the monovalent anti-c-MET antibody onartuzumab (MetMAb) in the second- and third-line non-small cell cung cancer. AAPS J. 19, 527-533, 2017.
  30. STROH M., WINTER H., MARCHAND M., CLARET L., EPPLER S., RUPPEL J., ABIDOYE O., TENG S.L., LIN A., DAYOG S., BRUNO R., JIN J., GIRISH S. – The clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clinical Pharmacology and Therapeutic, 102, 305-312, 2017.
  31. FACIUS A., KRAUSE A., CLARET L., BRUNO R., LAHU G. Modeling and simulation of pivotal clinical trials using linked models for multiple endpoints in chronic obstructive pulmonary disease with roflumilast. Journal of Clinical Pharmacology, 57, 1042-1052, 2017.
  32. EMENS LA, BRUNO R, RUBIN EH, JAFFEE EM, MCKEE AE. Report on the Third FDA- AACR Immuno-Oncology Dose-Finding Workshop. Cancer Immunology Research. 5, 1058-1061, 2017 (Invited Conference Report).
  33. HAN K., CLARET L., SANDLER A., DAS A., JIN J., BRUNO R. – Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation. BMC Cancer, 16, 473, 2016.
  34. HAN K., CLARET L., PIAO Y., HEGDE P., JOSHI A., POWELL J.R., JIN J., BRUNO R. – Simulations to predict clinical trial outcome of bevacizumab plus chemotherapy vs. chemotherapy alone in patients with first-line gastric cancer and elevated plasma VEGF-A. Clinical Pharmacology Therapeutics: Pharmacometrics and System Pharmacology, 5, 352-358, 2016.
  35. CLARET L., ZHENG J., MERCIER F., CHANU P., CHEN Y., ROSBROOK B., YAZDI P., MILLIGAN P.A., BRUNO R. – Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline. Cancer Chemotherapy Pharmacology, 78, 605-610, 2016
  36. CLARET L., BRUNO R., LU J.F., SUN Y.N. & HSU C.P. – Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study results. Clinical Pharmacology Therapeutics, 95, 446-451, 2014.
  37. CLARET L., MERCIER F., HOUK B.E., MILLIGAN P.A., BRUNO R. – Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients. Cancer Chemotherapy Pharmacology, 76, 567-573, 2015.
  38. HAN K., JIN J.Y., MARCHAND M., EPPLER S., CHOONG N.W., HACK S.P., TIKOO N., BRUNO R., DRESSER M.J., MUSIB L., BUDHA N.R. – Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemotherapy Pharmacology, 76, 917-924, 2015.
  39. JONSSON F., OU Y., CLARET L., SIEGEL D., JAGANNATH S., VIJ R., BADROS A., AGGARWAL S., BRUNO R. – A tumor growth inhibition model based on M-protein levels in subjects with relapsed/refractory multiple myeloma following single-agent carfilzomib use. Clinical Pharmacology Therapeutics: Pharmacometry and System Pharmacology, 4, 711-719, 2015.
  40. VENKATAKRISHNAN K, FRIBERG L, OUELLET D, METTETAL J, STEIN A, TROCONIZ I, BRUNO R, MEHROTRA N, GOBBURU J, MOULD D. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: Challenges and opportunities. Clinical Pharmacology and Therapeutics, 97, 37-54, 2015 (Invited State of the Art Paper).
  41. BRUNO R, MERCIER F, CLARET L. Evaluation of tumor-size response metrics to predict survival in oncology clinical trials. Clinical Pharmacology and Therapeutics, 95, 386-393, 2014 (Invited State of the Art paper).
  42. BRUNO R, MENTRE F, TANNENBAUM S, WANG Y, CORRIGAN B, MAGER DE. ISoP Standards and Best Practices Committee. Clinical Pharmacology and Therapeutics, 95, 581-582, 2014 (Invited Opinion).
  43. CLARET L, BRUNO R. On the assessment of tumor growth inhibition metrics to predict overall survival. Clinical Pharmacology and Therapeutics, 96,135-137, 2014 (invited Point/Couterpoint).
  44. CLARET L., GUPTA M., HAN K., JOSHI A., SARAPA N., HE J., POWELL B., BRUNO R. – Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first‐line non‐small cell lung cancer treated with chemotherapy with or without bevacizumab. Journal of Clinical Pharmacology, 54, 253-257, 2014.
  45. MERCIER F., CLARET L., PRINS K., BRUNO R. A model-based meta-analysis to compare efficacy and tolerability of tramadol and tapentadol for the treatment of chronic non-malignant pain. Pain and Therapy, 3, 31-44, 2014.
  46. CLARET L., GUPTA M., HAN K., JOSHI A., SARAPA N., HE J., POWELL B., BRUNO R. – Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. Journal of Clinical Oncology, 31, 2110-2114, 2013.
  47. BRUNO R, MERCIER F. CLARET L. Model-based drug development in oncology: What’s next. Clinical Pharmacology and Therapeutics, 93, 303-305, 2013 (Invited Commentary).
  48. PFISTER M, MAGER D.E, HOLFORD N.H.G, CORRIGAN B, TANNENBAUM S, BRUNO R, ZHANG L, WANG Y, D’ARGENIO DZ. The International Society of Pharmacometrics. Journal of Pharmacokinetics and Pharmacodynamics, 40 (Suppl.), 3-4, 2013 (Invited Commentary).
  49. CLARET L., LU J.-F., BRUNO R., HSU C.P., HEI H.J., SUN Y.N. – Simulations using a public domain drug-disease modeling framework and Phase II data predict Phase III survival outcome in first-line non-small-cell lung cancer (NSCLC). Clinical Pharmacology Therapeutics, 92, 631-634, 2012.
  50. BRUNO R., LINDBOM L., SCHAEDELI STARK F., CHANU P., GILBERG F., FREY N., CLARET L. – Simulations to assess Phase II non-inferiority trials of different doses of capecitabine in combination with docetaxel for metastatic breast cancer. Clinical Pharmacology Therapeutics: Pharmacometry and System Pharmacology, 1, e19, doi:10.1038/psp.2012.20, published online 26 December 2012.
  51. FRANCES N., CLARET L., BRUNO R., ILIADIS A. – Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 68, 1413-1419, 2011.
  52. BRUNO R, LU J-F, SUN Y-N, CLARET L. A Modeling and simulation framework to support early clinical drug development decisions in oncology. Journal of Clinical Pharmacology, 51, 6-8, 2011 (Invited Commentary).
  53. LU J.-F., CLARET L., SUTJANDRA L., KUCHIMANCHI M., MELARA R., BRUNO R., SUN Y.- N. – Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer Chemotherapy and Pharmacology, 66, 1151-1158, 2010.
  54. CLARET L., LU J.-F., SUN Y.-N., BRUNO R. – Development of a modeling framework to simulate efficacy endpoints for motesanib in thyroid cancer patients. Cancer Chemotherapy and Pharmacology, 66, 1141-1149, 2010.
  55. CLARET L., GIRARD P., HOFF P.M., VAN CUTSEM E., ZUIDEVELD K.P., JORGA K., FAGERBERG J., BRUNO R. – Model-based prediction of Phase III overall survival in colorectal cancer based on Phase II tumor dynamics. Journal of Clinical Oncology, 27, 4103-4108, 2009.
  56. BRUNO R, CLARET L. On the use of change in tumor size to predict survival in clinical oncology studies: Toward a new paradigm to design and evaluate Phase II studies. Clinical Pharmacology and Therapeutics, 86, 136-138, 2009 (Invited Commentary).
  57. LU J.-F., BRUNO R., EPPLER S., NOVOTNY W., LUM B. GAUDREAULT J. – Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 62, 779-786, 2008.
  58. CLARET L., COX E.H., MCFADYEN L., PIDGEN A., JOHNSON P.J., HAUGHIE S., BOOLELL M., BRUNO R. – Modelling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra). Pharmaceutical Research, 23, 1756-1764, 2006.
  59. LU J.-F., EPPLER S.M., WOLF J., HAMILTON M., RAKHIT A., BRUNO R., LUM B.L. – Clinical Pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clinical Pharmacology and Therapeutics, 80, 136-145, 2006.
  60. SUN Y.-N., LU J.-F., JOSHI A., COMPTON P., KWON P., BRUNO R. – Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. Journal of Clinical Pharmacology, 45, 468-476, 2005.
  61. BRUNO R., WASHINGTON C.B., LU J.-F., LIEBERMAN G., BANKEN L., KLEIN P. – Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 56, 361-369, 2005.
  62. NG C.M., BRUNO R., COMBS D., DAVIES B. – Population pharmacokinetic of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a Phase II clinical trial. Journal of Clinical Pharmacology, 45: 792-801, 2005.
  63. LEMENUEL-DIOT A., MALLET A., LAVEILLE C., BRUNO R. – Estimating heterogeneity in random effects models for longitudinal data. Biometrical Journal, 47: 329-345, 2005.
  64. BRUNO R., OLIVARES R., BERILLE J., CHAIKIN P., VIVIER N., HAMMERSHAIMB L., RHODES G.R., RIGAS J.R. – Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clinical Cancer Research, 9, 1077-1082, 2003.
  65. BRUNO R., BAILLE P., RETOUT S., VIVIER N., VEYRAT-FOLLET C., SANDERINK G.-J., BECKER R., ANTMAN E.R. – Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Brithish Journal of Clinical Pharmacology, 56, 407-414, 2003.
  66. RETOUT S., MENTRE F., BRUNO R. – Fisher information matrix for non-linear mixed-effects models: Evaluation and application for optimal design of enoxaparin population pharmacokinetics. Statistics in Medicine, 21, 2623 –2639, 2002.
  67. DIOT A., MALLET A., BRUNO R. – Adaptation des quadratures de Gauss-Hermite pour ameliorer l’estimation dans les modeles non lineaires a effets mixtes. Journal de la Société Francaise de Statistiques, 143, 195-204, 2002.
  68. HIRTH J., WATKINS P., STRAWDERMAN M., SCHOTT A., BRUNO R., BAKER L. – The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance. Clinical Cancer Research, 6, 1255-1258, 2000.
  69. SCHRIJVERS D., PRONK L., HIGHLEY M, BRUNO R., LOCCI-TONELLI D., DE BRUIJN E., VAN OOSTEROM A.T., VERWEIJ J. – Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. American Journal of Clinical Oncology, 23, 358-363, 2000.
  70. COUTEAU C., RISSE M.L., DUCREUX M., SOULAS F., RIVA A., LEBECQ A., RUFFIE P., ROUGIER P., LOKIEC F., BRUNO R., ARMAND J.P. – Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. Journal of Clinical Oncology, 18, 3545-3552, 2000.
  71. VEYRAT-FOLLET C., BRUNO R., OLIVARES R., RHODES G., CHAIKIN P. – Clinical trial simulation of docetaxel in cancer patients as a tool for dosage optimization. Clinical Pharmacology and Therapeutics, 68, 677-687, 2000.
  72. NEWMAN R.A., KIM J., NEWMAN B.M., BRUNO R., BAYSSAS M., KLINK-ALAKI M., PAZDUR R. – Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors. Anticancer Drugs, 10, 889-894, 1999.
  73. BRUNO R., HILLE D., RIVA A., VIVIER N., TEN BOKKEL HUINNINK W.W., VANOOSTEROM A.T., KAYE S.B., VERWEIJ J., FOSSELLA F.V., VALERO V., RIGAS J.R., SEIDMAN A.D., CHEVALIER B., FUMOLEAU P., BURRIS H.A., RAVDIN P.M., SHEINER L.B. – Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. Journal of Clinical Oncology, 16 (1), 187-196, 1998. Selected for reprint in Classic Papers and Current Comments – Highlights of Cancer Pharmacology Research, Ratain M.J. editor, 4 (1), 195-204, 1999.
  74. MCLEOD H.L., KEARN C.M., KUHN J.G., BRUNO R. – Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemotherapy and Pharmacology, 42, 155-159, 1998.
  75. MILLWARD M.J., ZALCBERG J., BISHOP J.F., WEBSTER L.K., ZIMET A., RISCHIN D., TONER G.C., LAIRD J., COSOLO W., URCH M., BRUNO R., LORET C., BLANC C. – Phase I trail of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology, 15 (2), 750-758, 1997.
  76. PRONK L.C., SCHELLENS J.M.H., PLANTING A.S.T., VAN DEN BENT M.J., HILKENS P.H.E., VAN DER BURG M.E.L., DE BOER-DENNERT M., BA J., BLANC C., HARTEVELD M., BRUNO R., STOTER G., VERWEIJ J. – Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. Journal of Clinical Oncology, 15 (3), 1071-1079, 1997.
  77. BAILLE P., BRUNO R., SCHELLENS J.H.M., WEBSTER L.K., MILLWARD M., VERWEIJ J., MONTAY G. – Optimal sampling strategies for Bayesian estimation of docetaxel (Taxotere) clearance. Clinical Cancer Research, 3(9), 1535-1538, 1997.
  78. BRUNO R., VIVIER N., MONTAY G., POWE L.K., LE LIBOUX A., DELUMEAU J.C., RHODES G. – Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clinical Pharmacology and Therapeutics, 62 (5), 518-526, 1997.
  79. ABIGERGES D., ARMAND J.P., CHABOT G.G., BRUNO R., BISSERY M.-C., BAYSSAS M., KLINK-ALAKL M., CLAVEL M., CATIMEL G. – Phase I and pharmacologic study of intoplicin (RP 60475, NSC 645008), a novel topoisomerase I and II inhibitor in cancer patients. Anticancer Drugs, 7, 166-174, 1996.
  80. HUDIS C.A., SEIDMAN A.D., CROWN J.P.A., BALMACEDA C., FREILICH R., GILEWSKI T.A., HAKES T.B., CURRIE V., LEBWOHL D.E., BALSEGA J., RAPTIS G., GOLLUB M., ROBLES M., BRUNO R., NORTON L. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. Journal of Clinical Oncology, 14, 58-65, 1996.
  81. BRUNO R., VIVIER N., VERGNIOL J.C., DE PHILLIPS S.L., MONTAY G., SHEINER L. B. – A population pharmacokinetic model for docetaxel (Taxotere) : Model building and validation. Journal of Pharmacokinetics and Biopharmaceutics, 24, 153-172, 1996.
  82. LAUNAY-ILIADIS M.C., BRUNO R., COSSON V., VERGNIOL J.C., OULID-AISSA D., MARTY M., CLAVEL M., AAPRO M., LEBAIL N., ILIADIS A. – Population pharmacokinetics of docetaxel using non linear mixed effect modelling (NONMEM) and non-parametric maximum likelihood (NPML) estimation. Cancer Chemotherapy and Pharmacology, 37, 47-54, 1995.
  83. FILLASTRE J.P., MONTAY G., BRUNO R., ETIENNE I., DHIB M., VIVIER N., LE ROUX Y., GUIMART C., GAY G., SCHOTT D. Pharmacokinetics of Sparfloxacin in patients with renal impairment. Antimicrobial Agents and Chemotherapy, 38 (4), 733-737, 1994.
  84. MONTAY G., BRUNO R., VERGNIOL J.C., EBMEIER M., LE ROUX Y., GUIMART C., FRYDMAN A., CHASSARD D., THEBAULT J.J. – Pharmacokinetics of Sparfloxacin in humans after single oral administration at doses of 200, 400, 600 and 800 mg. Journal of Clinical Pharmacology, 34, 1071-1076, 1994.
  85. LACARELLE B., LE GUELLEC C., MOREL A., ALBANESE J., ALAZIA M., BALLEREAU M., LIURENS M., BRUNO R., FRANCOIS G., DURAND A. – Monitoring of pefloxacin serum concentrations in intensive care unit patients : Comparison of a new immunoassay with high performance liquid chromatography. Therapeutics Drug Monitoring, 16, 209-213, 1994.
  86. EXTRA J.M., ROUSSEAU F., BRUNO R., CLAVEL M., LE BAIL N., MARTY M. – Phase I and pharmacokinetic study of Taxotere (RP 56976 ; NSC 628503) given as a short I.V. infusion, every 21 days. Cancer Research, 53, 1037-1042, 1993.
  87. Van GIJN R., ROSING H., Ten BOKKEL HUININK W.W., Van TELLINGEN O., VERMORKEN J.B., LIEFTING A.J.M., BRUNO R., PINEDO H. M., BEIJNEN J.H. – Determination of intoplicine, a new antitumor drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection. Journal of Chromatography, 614, 299-306, 1993.
  88. Van ROOIJ J., SCHOEMAKER H.C., BRUNO R., REINHOUDT J.F., BREIMER D.D., COHEN A.F. – Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine. British Journal of Clinical Pharmacology, 35, 661-663, 1993.
  89. BRUNO R., SANTONI Y., ILIADIS A., DJIANE P., SERRADIMIGNI A., CANO J.P. – Simultaneous modelling of mexiletine and hydroxy-methyl-mexiletine data after single-and multiple-dose administration of a sustained release mexiletine formulation. Biopharmaceutics and Drug Disposition, 13, 481-493, 1992.
  90. VERGNIOL J.C., BRUNO R., MONTAY G., FRYDMAN A. – Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. Journal of chromatography, 582, 273-278, 1992.
  91. BRUNO R., ILIADIS M.C., LACARELLE B., COSSON V., MANDEMA J.W., LE ROUX Y., MONTAY G., DURAND A., BALLEREAU M., ALASIA M., ALBANESE J., FRANCOIS G., ILIADIS A., FRYDMAN A. – Evaluation of Bayesian estimation in comparison of NONMEM for population pharmacokinetic data analysis : application to Pefloxacin in intensive care unit patients. Journal of Pharmacokinetics and Biopharmaceutics, 20(6), 653-669, 1992.
  92. PINQUIER J.L., SEDIVY P., BRUNO R., BOMPART F., GREGOIRE J., STRAUCH G., GAILLOT J., CLUCAS A. – Inhibition of ex-vivo PAF-induced platelet aggregation by the PAF- antagonist RP 48740: Relationship to plasma concentration in healthy volunteers. European Journal of Clinical Pharmacology, 41, 141-145, 1991.
  93. BRUNO R., JULLIEN I., AUGER J., ILIADIS A., DOW R., Mc EWEN J., CANO J.P., PINHAS H. – Multiple-dose pharmacokinetics of the new H1-receptor antagonist Tazifylline in healthy volunteers. Biopharmaceutics and Drug Disposition, 10, 115-119, 1989.
  94. FRYDMAN A., CHAPELLE P., DIEKMANN H., BRUNO R., THEBAULT J.J., BOUTHIER J., CAPLAIN H., UNGETHUEM W., GAILLARD C., LE LIBOUX A., RENARD A., GAILLOT J. Pharmacokinetics of Nicorandil. American Journal of Cardiology, 63 (21), 25J-33J, 1989.
  95. ILIADIS A., BRUNO R., CANO J.P. – Dynamical dosage regimen calculations in linear pharmacokinetics Computer and Biomedical Research, 21, 203-220, 1988.
  96. BRUNO R., ILIADIS A., JULLIEN I., GUEGO M., PINHAS H., CUNCI S., CANO J.P. – Naproxen kinetics in synovial fluid of patients with osteoarthritis. British Journal of Clinical Pharmacology, 26, 41-44, 1988.
  97. BORE P., BRUNO R., LENA N., FAVRE R., CANO J.P. – Methotrexate and 7-hydroxy-methotrexate pharmacokinetics following intravenous bolus administration and high-dose infusion of methotrexate. European Journal of Cancer and Clinical Oncology, 23 (9), 1385-1390, 1987.
  98. RHAMANI R., BRUNO R., ILIADIS A., FAVRE R., JUST S., BARBET J., CANO J.P. – Clinical pharmacokinetics of the antitumor drug navelbine (5′-noranhydrovinblastine). Cancer Research, 47, 5796-5799, 1987.
  99. ILIADIS A., BRUNO R., CANO J.P. – Steady-state dosage regimen calculations in linear pharmacokinetics. International Journal of Biomedical Computing, 18, 167-182, 1986.
  100. ILIADIS A., BACHIR-RAHO M., BRUNO R., FABRE R. – Bayesian estimation and clearance prediction in high dose methotrexate infusions. Journal of Pharmacokinetics and Biopharmaceutics, 13, 101-115, 1985.
  101. CANO J.P., BRUNO R., LENA N., FAVRE R., ILIADIS A., IMBERT A.M. – Dosage predictions in high-dose methotrexate infusions. Part 1 : Evaluation of the classic test-dose protocol. Cancer Drug Delivery, 2, 271-276, 1985.
  102. BRUNO R., ILIADIS A., FAVRE R., LENA N., IMBERT A.M., CANO J.P. – Dosage predictions in high-dose methotrexate infusions. Part 2 : Bayesian estimation of methotrexate clearance. Cancer Drug Delivery, 2, 277-283, 1985.
  103. MARCHISET D., BRUNO R., DJIANE P., CANO J.P., SERRADIMIGNI A. Amiodarone and desethylamiodarone elimination kinetics following withdrawal of long-term therapy. Biopharmaceutics and Drug Disposition, 6, 209-215, 1985.
  104. BRUNO R., GRANDVUILLEMIN M., OLMER M., CANO J.P. – Cinétiques plasmatiques de l’acétate, du bicarbonate et intolérance à l’acétate durant et après dialyse rénale. Pathologie Biologie, 32 (7), 768-771, 1984.
  105. BRUNO R., ILIADIS A., BOTTA A., MARIOTTI B., JULLIEN G., CANO J.P. – Pharmacokinetic study of ethanol after oral administration : a new approach to enzymatic elimination. Clinical Pharmacology Therapy and Toxicology, 21 (7), 363-369, 1983.
  106. BRUNO R., ILIADIS A., TREFFOT M.J., MARIOTTI B., CANO J.P., JULLIEN G. – Non-linear kinetics of ethanol elimination in man: medico-legal applications of the terminal concentration- time data analysis. Forensic Science International, 21, 207-213, 1983.
  107. SANTONI Y., BRUNO R., FORNARIS M., EGRE A., DANAYS T., CANO J.P. – Pharmacocinétique et biodisponibilité relative chez le sujet sain d’une nouvelle forme orale de mexilétine à libération continue. Thérapie, 38, 341-344, 1983.
  108. BRUNO R., ILIADIS A., TREFFOT M.J., MARIOTTI B., CANO J.P., JULLIEN G. – Evolution of plasma acetate concentration during ethanol metabolism in man. Forensic Science International, 21, 215-221, 1983. R Bruno – June 2018 5
  109. BRUNO R., SANTONI Y., BOTTA A., CANO J.P. – Mise au point d’une méthode de dosage par chromatographie en phase gazeuse de l’acétate plasmatique après administration d’éthanol chez l’homme. Toxicological European Research, IV (1), 31-34, 1982.
  110. BRUNO R., ILIADIS A., SANTONI Y., BOTTA A., MARIOTTI B., TREFFOT M.J., CANO J.P. – Approche du métabolisme de l’éthanol chez l’homme par l’étude de l’évolution de l’alcoolémie, de la concentration d’enzyme libre et du taux d’acétate plasmatique. Toxicological European Research, IV (2), 71-75, 1982.
  111. BOTTA A., SANTONI Y., BRUNO R., BRAS B., MARIOTTI B., MATHIAS A., JULLIEN G. – Intérêt pratique du dosage de la protoporphyrine libre érythrocytaire dans le dépistage précoce de l’exposition professionnelle au plomb et dérivés minéraux. Revue de Médecine du Travail, VIII (3), 143-148, 1980.
More publications